Sperling, A. S., Nikiforow, S., Derman, B., Nadeem, O., Mo, C., Laubach, J., Anderson, K., Alonso, A., Im, S., Ikwgawa, S., Prabhala, R., Hernandez Rodriduez, D., Daley, H., Shaw, K. L., Arihara, Y., Ansari, S., Quinn, D. S., Pearson, D., Hack, A., Treanor, L., Bu, D., Mataraza, J., Rispoli, L., Credi, M., Ritz, J., Jakubowiak, A., De Vita, S., & Munshi, N. (n.d.). p1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA-DIRECTED CAR-T CELL THERAPY MANUFACTURED USING THE T-CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM). HemaSphere, 6, 1329–1330. http://access.bl.uk/ark:/81055/vdc_100159757189.0x000016